Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
0.104
-0.004 (-3.61%)
At close: Nov 22, 2024, 4:00 PM
0.100
-0.004 (-3.85%)
After-hours: Nov 22, 2024, 7:59 PM EST
Company Description
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave’s disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Conduit Pharmaceuticals Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | David Tapolczay |
Contact Details
Address: 4995 Murphy Canyon Road, Suite 300 San Diego, California 92123 United States | |
| Phone | 760 471 8536 |
| Website | conduitpharma.com |
Stock Details
| Ticker Symbol | CDT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001896212 |
| CUSIP Number | 20678X106 |
| ISIN Number | US20678X1063 |
| Employer ID | 87-3272543 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Joszef Tapolczay | Chief Executive Officer and Director |
| James Bligh | Interim Chief Financial Officer and Director |
| Dr. Joanne M. Holland | Chief Scientific Officer |
| Bill Begien | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 14, 2024 | 10-Q/A | [Amend] Quarterly report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 424B5 | Filing |
| Nov 4, 2024 | 424B3 | Prospectus |
| Nov 1, 2024 | EFFECT | Notice of Effectiveness |
| Nov 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |